A detailed history of Newbridge Financial Services Group, Inc. transactions in Verve Therapeutics, Inc. stock. As of the latest transaction made, Newbridge Financial Services Group, Inc. holds 252 shares of VERV stock, worth $1,146. This represents 0.0% of its overall portfolio holdings.

Number of Shares
252
Previous 562 55.16%
Holding current value
$1,146
Previous $2,000 50.0%
% of portfolio
0.0%
Previous 0.0%

Shares

4 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q3 2024

Nov 12, 2024

SELL
$4.4 - $7.86 $1,364 - $2,436
-310 Reduced 55.16%
252 $1,000
Q2 2024

Sep 11, 2024

SELL
$4.76 - $12.79 $476 - $1,279
-100 Reduced 15.11%
562 $2,000
Q1 2024

Apr 24, 2024

SELL
$10.81 - $17.96 $16,431 - $27,299
-1,520 Reduced 69.66%
662 $8,000
Q4 2023

Mar 28, 2024

BUY
$8.84 - $18.7 $19,288 - $40,803
2,182 New
2,182 $30,000

Others Institutions Holding VERV

About Verve Therapeutics, Inc.


  • Ticker VERV
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 59,942,300
  • Market Cap $273M
  • Description
  • Verve Therapeutics, Inc., a genetic medicines company, engages in developing gene editing medicines for patients to treat cardiovascular diseases. Its lead product candidate is VERVE-101, a single-course gene editing treatment that permanently turns off the PCSK9 gene in the liver. The company also engages in the development of ANGPTL3 program t...
More about VERV
Track This Portfolio

Track Newbridge Financial Services Group, Inc. Portfolio

Follow Newbridge Financial Services Group, Inc. and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Newbridge Financial Services Group, Inc., based on Form 13F filings with the SEC.

News

Stay updated on Newbridge Financial Services Group, Inc. with notifications on news.